Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Executive Summary

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

Advertisement

Related Content

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?
BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases
BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases
Pharma Q4 Results Preview: Shire, Bayer, Merck KGaA
Merck KGAA Courts US, China Investors To Accelerate Immuno-Oncology Development
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel